United Therapeutics UTHR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.29B+6.3% | $1.33B+11.7% | $1.27B+14.5% | $1.24B+16.1% | $1.21B+15.2% | ||
| $88.4M+14.4% | $85.6M+18.1% | $82.5M+24.1% | $79.7M+31.3% | $77.3M+40.8% | ||
| $149.8M-0.3% | $147.7M+2.6% | $135.7M+1.6% | $138.3M+22.4% | $150.2M+94.8% | ||
| —— | —— | —— | —— | -$48.08M+25.3% | ||
| —— | —— | —— | —— | —— | ||
| $81.5M+67.0% | $52.6M+12.2% | $47.7M+12.8% | $41.5M+21.7% | $48.8M+139% | ||
| $87.8M— | $97.9M— | —— | —— | —— | ||
| $188.4M+379% | $80.9M+1,052% | -$44.3M— | -$19.5M— | -$67.5M— | ||
| —— | —— | —— | —— | —— | ||
| $1.56B+10.7% | $1.56B+17.6% | $1.56B+36.9% | $1.37B+24.0% | $1.41B+44.1% | ||
| $546.4M+92.9% | $520.5M+111% | $434.3M+82.1% | $300.3M+31.9% | $283.2M+24.6% | ||
| $3.41B+88.8% | $3.41B+107% | $3.36B+128% | $3.39B+97.7% | $1.81B-16.0% | ||
| $3.17B— | $1.86B— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.5B— | $1B— | —— | —— | —— | ||
| —— | —— | —— | $700M+133% | $400M+100% | ||
| $225.6M+77.8% | $173.9M+14.0% | $100.6M-25.0% | $92.9M-12.5% | $126.9M+61.0% | ||
| $59.6M+270% | $16.6M+36.1% | $16.3M+35.8% | $16.2M+37.3% | $16.1M+37.6% | ||
| -$2.64B-840% | -$1.25B+0.5% | -$1.32B-3.9% | -$431.2M+64.1% | -$280.6M+75.1% | ||
| —— | —— | -$213.8M-148% | $237.4M-17.7% | $648.4M— | ||
| $10M-69.7% | $13.5M-66.4% | $18.7M-60.4% | $26.4M-49.4% | $33M-40.5% | ||
| $314.3M-20.7% | $313.3M-21.8% | $373.6M-3.2% | $442.5M+11.5% | $396.4M+17.6% | ||
| -$8.2M-185% | $19.7M-18.9% | -$11.3M-142% | -$5.7M— | $9.7M— | ||
| —— | —— | $21.5M-31.1% | $33.6M+40.0% | $33.4M+22.3% | ||
| $80M— | $55M— | $60M— | —— | —— | ||
| $1.24B-25.8% | $1.58B+3.1% | $1.58B-0.6% | $1.78B+10.9% | $1.67B-12.1% | ||
| $3.17B— | $1.86B— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $168.7M— | $116.3M— | —— | —— | —— | ||
| $314.3M-20.7% | $313.3M-21.8% | $373.6M-3.2% | $442.5M+11.5% | $396.4M+17.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.02B-9.9% | $1.04B-3.7% | $1.12B+24.9% | $1.07B+22.0% | $1.13B+50.0% | ||
| $1.02B-9.9% | $1.04B-3.7% | $1.12B+24.9% | $1.07B+22.0% | $1.13B+50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does United Therapeutics generate?
- United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
- What is United Therapeutics's free cash flow?
- After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
- Where does United Therapeutics's cash flow data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
